Lab21

Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round. 

The clinical diagnostics company will use the funds to invest in a new UK-based manufacturing facility and to accelerate global growth.

Lab21 will serve as a non-exclusive distributor of the SelectMDx prostate cancer test in the UK.